摘要
背景:骨质疏松症是一种以骨微结构退化为特征的致脆性骨折的衰弱性疾病.。目前,用双联法测定骨密度(BMD)能量X线吸收仪(DXA)是诊断骨质疏松和管理药物治疗方案最可靠的方法.然而,骨密度的变化缓慢(即几个月)和DXA不能反映骨代谢的代谢率。另外,生化骨转换标记是释放到血清和/或尿液中的代谢指标,它们的数量反映了我。骨代谢活性。骨转换标记物在给药后表现出快速反应,酶联免疫吸附试验(ELISA)已经建立并应用于CLI。帮助评估和预测独立于BMD的骨折风险的临床试验。 目的:本综述重点介绍了临床应用的各种骨转换指标,作为可靠和标准化的骨转换指标,并注意使用的指标。评估双膦酸盐药物治疗的疗效,特别是监测绝经后骨质疏松患者的药物依从性。 结果:我们认为,在常规临床访问中使用免疫分析法或ELISA法测定尿骨转换标记值,可能对医护人员和Pati有价值的反馈。Ents帮助监测双膦酸盐治疗和疾病进展的疗效和依从性。
关键词: 护理点试验,临床应用,双膦酸盐,骨转换标志,尿,骨吸收,ELISA,绝经后骨质疏松症。
图形摘要
Current Drug Targets
Title:Urinary Bone Turnover Markers as Target Indicators for Monitoring Bisphosphonate Drug Treatment in the Management of Osteoporosis
Volume: 19 Issue: 5
关键词: 护理点试验,临床应用,双膦酸盐,骨转换标志,尿,骨吸收,ELISA,绝经后骨质疏松症。
摘要: Background: Osteoporosis is a debilitating disease characterized by bone micro-architecture degradation contributing to fragility fractures. Currently, determining bone mineral density (BMD) via dual-energy X-ray absorptiometry (DXA) is the most reliable form of diagnosing osteoporosis and managing pharmacological treatment regimens. However, changes in BMD occur slowly (i.e., several months) and DXA does not reflect the metabolic rate of bone turnover. Alternatively, biochemical bone turnover markers are metabolic indicators released into serum and/or urine, and their quantity reflects the metabolic activity of bone. bone turnover markers show a rapid response following antiresorptive drug administration, and enzyme-linked immunosorbent assays (ELISA) have been established and used in clinical trials to help assess and predict fracture risk independent of BMD.
Objective: This review highlights various established bone turnover markers that have found utility in the clinic as reliable and standardized indicators of bone turnover, with attention to those used to assess efficacy of bisphosphonate drug therapy – particularly in monitoring medication adherence in patients with postmenopausal osteoporosis.
Results: We posit that the use of urinary bone turnover markers values determined by immunoassay or ELISA at routine clinic visits might serve as valuable feedback to healthcare professionals and patients to help monitor the efficacy and adherence of bisphosphonate therapy and disease progression.
Conclusion: Our belief is that when assessed in combination with an algorithm of independent risk factors, measuring urinary bone turnover markers using a point of care kit may find utility in the osteoporosis clinic as an accessible, non-invasive and cost-effective alternative for the routine assessment of efficacy of bisphosphonate therapies.
Export Options
About this article
Cite this article as:
Urinary Bone Turnover Markers as Target Indicators for Monitoring Bisphosphonate Drug Treatment in the Management of Osteoporosis, Current Drug Targets 2018; 19 (5) . https://dx.doi.org/10.2174/1389450118666170704143529
DOI https://dx.doi.org/10.2174/1389450118666170704143529 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers